Sage Therapeutics Inc. (SAGE) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Sage Therapeutics Inc. (SAGE)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

7.46

-0.04 (-0.53%)

At close: Jan 14, 2025, 3:59 PM

7.40

-0.69%

Pre-market Jan 15, 2025, 08:00 AM EST

undefined% (undefined)

Bid	7.4
Market Cap	456.05M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-5.57
PE Ratio (ttm)	-1.34
Forward PE	n/a
Analyst	Hold

Ask	7.44
Volume	3,365,282
Avg. Volume (20D)	1,253,822
Open	7.53
Previous Close	7.50
Day's Range	7.41 - 7.65
52-Week Range	4.62 - 27.68
Beta	undefined

About SAGE

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 18, 2014

Employees 487

Stock Exchange NASDAQ

Ticker Symbol SAGE

Website https://www.sagerx.com

Analyst Forecast

According to 19 analyst ratings, the average rating for SAGE stock is "Hold." The 12-month stock price forecast is $9, which is an increase of 20.72% from the latest price.

Buy 10.53%

Hold 73.68%

Sell 10.53%

Stock Forecasts

Next Earnings Release

Sage Therapeutics Inc. is scheduled to release its earnings on Feb 12, 2025, before market opens.
Analysts project revenue of $14.11M, reflecting a -81.9% YoY shrinking and earnings per share of -1.38, making a 150.91% increase YoY.

Why Price Moved

2 days ago · Source

+35.14%

Sage Therapeutics shares are trading higher after ... Unlock content with Pro Subscription

2 months ago · Source

-24.06%

Sage Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results. Additionally, HC Wainwright & Co. cut its price target on the stock from $25 to $14.

News

1 day ago · zacks.com

Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?

Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more s...

1 day ago · zacks.com

Biogen Offers to Buy Remaining Stake in Sage Therapeutics

Biogen offers to buy the remaining stake in Sage Therapeutics for $7.22 per share. SAGE stock rises.

2 days ago · proactiveinvestors.com

Sage Therapeutics shares surge on unsolicited takeover bid from Biogen

Sage Therapeutics (NASDAQ:SAGE) stock soared after the firm announced that it had received an unsolicited takeover bid from Biogen Inc (NASDAQ:BIIB, ETR:IDP). Biogen has proposed to acquire all of Sag...

2 days ago · https://thefly.com

Sage takeout bid implies zero enterprise value, says Mizuho

Sage Therapeutics + Biogen -0.36 (-0.24%)

2 days ago · schaeffersresearch.com

Sage Therapeutics Stock Headed for Best Day in 5 Years

Biotech stock Sage Therapeutics Inc (NASDAQ:SAGE) is skyrocketing today, up 33.7% to trade at $7.42 at last glance, after Biogen's (BIIB) proposed takeover, which the company said on Friday it would c...

2 days ago · investopedia.com

Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid

Sage Therapeutics (SAGE) shares soared nearly 40% Monday on news Biogen (BIIB) is offering to buy the rest of the Sage stock it doesn't already own for $7.22 per share.

2 days ago · https://thefly.com

Biogen bid for Sage does not change narrative, says BMO Capital

Biogen -1.98 (-1.31%) Sage Therapeutics -0.29 (-4.96%)

2 days ago · benzinga.com

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?

On Friday, Sage Therapeutics Inc. SAGE confirmed that Biogen Inc. BIIB submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by ...

2 days ago · https://thefly.com

Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist

Sage Therapeutics -0.29 (-4.96%) Biogen -1.98 (-1.31%)

2 days ago · https://thefly.com

BofA moves to No Rating on Sage Therapeutics after Biogen bid

Sage Therapeutics -0.29 (-4.96%) Biogen -1.98 (-1.31%)

2 days ago · barrons.com

Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen

The biopharmaceutical company says its board of directors will now review and evaluate the offer from Biogen.

3 days ago · businesswire.com

Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer Barry Greene will discuss the Company's strategic focus areas for 2025 at the 43r...

5 days ago · businesswire.com

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today confirmed that Biogen Inc. (Nasdaq: BIIB) (“Biogen”) has submitted to the Company an unsolicited, nonbi...

1 week ago · businesswire.com

Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2...

1 week ago · zacks.com

Wall Street Analysts Believe Sage Therapeutics (SAGE) Could Rally 42.02%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 42% in Sage Therapeutics (SAGE). While the effectiveness of this highly sought-after metric is questionable, th...

3 weeks ago · zacks.com

Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?

Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength do...

1 month ago · businesswire.com

Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that the Company will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference o...

1 month ago · zacks.com

SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study

Sage Therapeutics' pipeline setbacks continue as the phase II DIMENSION study on dalzanemdor for treating Huntington's disease fails to meet the primary goal.

1 month ago · benzinga.com

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder

On Wednesday, Sage Therapeutics Inc SAGE revealed topline results from the Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) in participants with cognitive impairment (CI) associated with Huntington's...

1 month ago · marketwatch.com

Sage Therapeutics to end Huntington's disease trial after key therapy fails again

It was the third failed trial for the therapy, called dalzanemdor, which also failed to meet its goals in a Phase 2 trial as a treatment for mild cognitive impairment and mild dementia in Alzheimer's ...

Load More News